Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy
[Display omitted] One of the leading causes of mortality in the world is cancer. This disease occurs when responsible genes that regulate the cell cycle become inactive due to internal or external factors. Specifically, the G1/S and S/G2 transitions in the cell cycle are controlled by a protein call...
Gespeichert in:
| Veröffentlicht in: | Bioorganic chemistry 2024-02, Vol.143, p.107045-107045, Article 107045 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107045 |
|---|---|
| container_issue | |
| container_start_page | 107045 |
| container_title | Bioorganic chemistry |
| container_volume | 143 |
| creator | Patel, Dharmesh A. Patel, Siddharth S. Patel, Hitesh D. |
| description | [Display omitted]
One of the leading causes of mortality in the world is cancer. This disease occurs when responsible genes that regulate the cell cycle become inactive due to internal or external factors. Specifically, the G1/S and S/G2 transitions in the cell cycle are controlled by a protein called cyclin-dependent kinase 2 (CDK2). CDKs, which play a crucial role in managing the cell cycle, have been a wide area of research in cancer treatment. Over the past 11 years, significant research has been made in identifying potent, targeted, and efficient inhibitors of CDK2. In this summary, we have summarized recent developments in the synthesis and biological evaluation of CDK2 inhibitors. |
| doi_str_mv | 10.1016/j.bioorg.2023.107045 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2906773577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S004520682300706X</els_id><sourcerecordid>2906773577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-8f51042ee13bcabe69bb8ce21a8f8b107c984e78ab95236fb5ea4ea6d4a500b23</originalsourceid><addsrcrecordid>eNp9kM1OwzAQhC0EoqXwBgj5yCXFdhLHuSBV5VdU4kLPlu1sWldpXOykUt8eVykcOax2tZqZ1X4I3VIypYTyh81UW-f8asoIS-OqIFl-hsaUlCRhlJFzNCZxlTDCxQhdhbAhhNKs4JdolIo4FIKP0XJW7VVrIGDb4nBouzUEG7BqKxzjG7eyRjUY9qrpVWddi12N508fLMrXVtvO-YBr57E5hngc7V7tDtfoolZNgJtTn6Dly_PX_C1ZfL6-z2eLxKScdYmoc0oyBkBTbZQGXmotDDCqRC10fMmUIoNCKF3mLOW1zkFloHiVqZwQzdIJuh9yd9599xA6ubXBQNOoFlwfJCsJL4o0jzVB2SA13oXgoZY7b7fKHyQl8ghUbuQAVB6BygFotN2dLvR6C9Wf6ZdgFDwOAoh_7i14GYyFCKOyHkwnK2f_v_ADiIeJPQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2906773577</pqid></control><display><type>article</type><title>Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy</title><source>Elsevier ScienceDirect Journals</source><creator>Patel, Dharmesh A. ; Patel, Siddharth S. ; Patel, Hitesh D.</creator><creatorcontrib>Patel, Dharmesh A. ; Patel, Siddharth S. ; Patel, Hitesh D.</creatorcontrib><description>[Display omitted]
One of the leading causes of mortality in the world is cancer. This disease occurs when responsible genes that regulate the cell cycle become inactive due to internal or external factors. Specifically, the G1/S and S/G2 transitions in the cell cycle are controlled by a protein called cyclin-dependent kinase 2 (CDK2). CDKs, which play a crucial role in managing the cell cycle, have been a wide area of research in cancer treatment. Over the past 11 years, significant research has been made in identifying potent, targeted, and efficient inhibitors of CDK2. In this summary, we have summarized recent developments in the synthesis and biological evaluation of CDK2 inhibitors.</description><identifier>ISSN: 0045-2068</identifier><identifier>EISSN: 1090-2120</identifier><identifier>DOI: 10.1016/j.bioorg.2023.107045</identifier><identifier>PMID: 38147786</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anticancer ; Antiproliferative activity ; CDK2 enzyme ; CDK2 inhibitor ; Cell cycle arrest</subject><ispartof>Bioorganic chemistry, 2024-02, Vol.143, p.107045-107045, Article 107045</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-8f51042ee13bcabe69bb8ce21a8f8b107c984e78ab95236fb5ea4ea6d4a500b23</citedby><cites>FETCH-LOGICAL-c362t-8f51042ee13bcabe69bb8ce21a8f8b107c984e78ab95236fb5ea4ea6d4a500b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S004520682300706X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38147786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patel, Dharmesh A.</creatorcontrib><creatorcontrib>Patel, Siddharth S.</creatorcontrib><creatorcontrib>Patel, Hitesh D.</creatorcontrib><title>Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy</title><title>Bioorganic chemistry</title><addtitle>Bioorg Chem</addtitle><description>[Display omitted]
One of the leading causes of mortality in the world is cancer. This disease occurs when responsible genes that regulate the cell cycle become inactive due to internal or external factors. Specifically, the G1/S and S/G2 transitions in the cell cycle are controlled by a protein called cyclin-dependent kinase 2 (CDK2). CDKs, which play a crucial role in managing the cell cycle, have been a wide area of research in cancer treatment. Over the past 11 years, significant research has been made in identifying potent, targeted, and efficient inhibitors of CDK2. In this summary, we have summarized recent developments in the synthesis and biological evaluation of CDK2 inhibitors.</description><subject>Anticancer</subject><subject>Antiproliferative activity</subject><subject>CDK2 enzyme</subject><subject>CDK2 inhibitor</subject><subject>Cell cycle arrest</subject><issn>0045-2068</issn><issn>1090-2120</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OwzAQhC0EoqXwBgj5yCXFdhLHuSBV5VdU4kLPlu1sWldpXOykUt8eVykcOax2tZqZ1X4I3VIypYTyh81UW-f8asoIS-OqIFl-hsaUlCRhlJFzNCZxlTDCxQhdhbAhhNKs4JdolIo4FIKP0XJW7VVrIGDb4nBouzUEG7BqKxzjG7eyRjUY9qrpVWddi12N508fLMrXVtvO-YBr57E5hngc7V7tDtfoolZNgJtTn6Dly_PX_C1ZfL6-z2eLxKScdYmoc0oyBkBTbZQGXmotDDCqRC10fMmUIoNCKF3mLOW1zkFloHiVqZwQzdIJuh9yd9599xA6ubXBQNOoFlwfJCsJL4o0jzVB2SA13oXgoZY7b7fKHyQl8ghUbuQAVB6BygFotN2dLvR6C9Wf6ZdgFDwOAoh_7i14GYyFCKOyHkwnK2f_v_ADiIeJPQ</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Patel, Dharmesh A.</creator><creator>Patel, Siddharth S.</creator><creator>Patel, Hitesh D.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240201</creationdate><title>Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy</title><author>Patel, Dharmesh A. ; Patel, Siddharth S. ; Patel, Hitesh D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-8f51042ee13bcabe69bb8ce21a8f8b107c984e78ab95236fb5ea4ea6d4a500b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anticancer</topic><topic>Antiproliferative activity</topic><topic>CDK2 enzyme</topic><topic>CDK2 inhibitor</topic><topic>Cell cycle arrest</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patel, Dharmesh A.</creatorcontrib><creatorcontrib>Patel, Siddharth S.</creatorcontrib><creatorcontrib>Patel, Hitesh D.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patel, Dharmesh A.</au><au>Patel, Siddharth S.</au><au>Patel, Hitesh D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy</atitle><jtitle>Bioorganic chemistry</jtitle><addtitle>Bioorg Chem</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>143</volume><spage>107045</spage><epage>107045</epage><pages>107045-107045</pages><artnum>107045</artnum><issn>0045-2068</issn><eissn>1090-2120</eissn><abstract>[Display omitted]
One of the leading causes of mortality in the world is cancer. This disease occurs when responsible genes that regulate the cell cycle become inactive due to internal or external factors. Specifically, the G1/S and S/G2 transitions in the cell cycle are controlled by a protein called cyclin-dependent kinase 2 (CDK2). CDKs, which play a crucial role in managing the cell cycle, have been a wide area of research in cancer treatment. Over the past 11 years, significant research has been made in identifying potent, targeted, and efficient inhibitors of CDK2. In this summary, we have summarized recent developments in the synthesis and biological evaluation of CDK2 inhibitors.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38147786</pmid><doi>10.1016/j.bioorg.2023.107045</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0045-2068 |
| ispartof | Bioorganic chemistry, 2024-02, Vol.143, p.107045-107045, Article 107045 |
| issn | 0045-2068 1090-2120 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2906773577 |
| source | Elsevier ScienceDirect Journals |
| subjects | Anticancer Antiproliferative activity CDK2 enzyme CDK2 inhibitor Cell cycle arrest |
| title | Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A01%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20synthesis%20and%20biological%20evaluation%20of%20CDK2%20inhibitors%20for%20cancer%20therapy&rft.jtitle=Bioorganic%20chemistry&rft.au=Patel,%20Dharmesh%20A.&rft.date=2024-02-01&rft.volume=143&rft.spage=107045&rft.epage=107045&rft.pages=107045-107045&rft.artnum=107045&rft.issn=0045-2068&rft.eissn=1090-2120&rft_id=info:doi/10.1016/j.bioorg.2023.107045&rft_dat=%3Cproquest_cross%3E2906773577%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2906773577&rft_id=info:pmid/38147786&rft_els_id=S004520682300706X&rfr_iscdi=true |